Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy.
Lipodystrophies associated with HIV disease have been reported in recent years and have included a general redistribution of fat with more central fat and increased dorsocervical fat. These lipodystrophies are commonly associated with hyperlipidemia and in some cases with insulin resistant diabetes. Although a similar redistribution of fat is seen in hypercortisolism, in general, serum and urinary cortisol levels are normal in these HIV-positive patients. However cortisol/dehydroepaindrosterone (DHEA) ratios are increased in HIV disease and may result in a relative hypercortisolism. Seven HIV-positive male patients on multidrug antiviral therapy including HIV protease inhibitors had developed increased central and dorsocervical fat over 1 year. All patients had increased serum lipids and three had insulin resistant diabetes. Four patients were treated initially with DHEA 100-200 mg/day, with addition of a cyclo-oxygenase (COX) inhibitor (indomethacin 100 mg/day) and three others were treated from the onset with a combination of DHEA 200 mg/day and a COX inhibitor (indomethacin 100 mg/day or naprosyn 1000 mg/day). All patients reported moderation or normalization of their serum lipids and some moderation of blood sugars while on DHEA alone. More marked improvement in blood sugar and noticeable decreases in the dorsocervical fat; however, occurred only with addition a COX inhibitor. Both DHEA and COX inhibitors have a number of mechanisms of action; among these is their role as a peroxisome proliferator-activator receptor ligand. Dysregulation of peroxisome function is associated with the spectrum of biochemical changes seen within these HIV associated lipodystrophies. Use of HIV protease inhibitors is reported in the majority of patients with these lipodystrophies, and protease inhibitors may accentuate the underlying peroxisome dysregulation. Supplementation with DHEA and a COX inhibitor may improve peroxisomal function.
Smith
K J
KJ
Department of Dermatology, National Naval Medical Center, Bethesda, Maryland, USA.
Skelton
H G
HG
D019380:Anti-HIV Agents / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008060:Lipodystrophy / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use; D018901:Peroxisomal Disorders / Q000188:drug therapy* / Q000821:virology; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use*; D014157:Transcription Factors / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D016861:Cyclooxygenase Inhibitors; D017320:HIV Protease Inhibitors; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D003687:Dehydroepiandrosterone; D009288:Naproxen; D007213:Indomethacin